Myositis Studies
The Division of Rheumatology strives to understand more myositis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
VALOR IRB# 22-2265 Elena Weinstein, MD | To investigate the efficacy and safety of oral brepocitinib in individuals with dermatomyositis To review the clinical trials.gov info click here | Seeking participants 18-75 years old with a diagnosis of dermatomyositis who have current skin and muscle involvement. | Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
HORIXON-DAX IRB# 23-0062 Elena Weinstein, MD | A proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis or anti-synthetase inflammatory myositis To review the clinical trials.gov info click here | -Diagnosis of dermatomyositis or anti-synthetase inflammatory myositis with active skin disease. -Must be willing to stop IVIG at screening (if applicable) | Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.